Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gammaitoni

Showing results (161-170 of 230) with videos related to

Pageof 23
Sort By:
International Journal of Rheumatic Diseases|June 12, 2010
Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trialHsiao-Yi Lin, Tien-Tsai Cheng, Jyh-Horng Wang, et al.
Cardiovascular Therapeutics|September 3, 2011
Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugsHenry Krum, Gary Swergold, Arnold Gammaitoni, et al.
Current Medical Research and Opinion|June 29, 2012
Perioperative use of etoricoxib reduces pain and opioid side-effects after total abdominal hysterectomy: a double-blind, randomized, placebo-controlled phase III studyEugene R Viscusi, Tara L Frenkl, Craig T Hartrick, et al.
Breast Cancer Research and Treatment|December 15, 2010
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenibGiorgio Valabrega, Sonia Capellero, Giuliana Cavalloni, et al.
Human Gene Therapy|August 15, 2009
T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCRPaola Circosta, Luisa Granziero, Antonia Follenzi, et al.
Seizure|November 12, 2021
Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndromeJ Helen Cross, Bradley S Galer, Antonio Gil-Nagel, et al.
EJIFCC|October 23, 2023
Inter-laboratory method validation of CD34+ flow-cytometry assay: the experience of Turin Metropolitan Transplant CentreI F Ivana Ferrero, D R Deborah Rustichelli, S C Sara Castiglia, et al.
Journal of Biotechnology|September 22, 2011
Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34(+) cells and T lymphocytes: implications for the use of low viral doses and large-size vectorsValeria Leuci, Giulia Mesiano, Loretta Gammaitoni, et al.
Frontiers in Oncology|February 23, 2023
Case report: Preclinical efficacy of NEDD8 and proteasome inhibitors in patient-derived models of signet ring high-grade mucinous colorectal cancer from a Lynch syndrome patientErica Torchiaro, Consalvo Petti, Sabrina Arena, et al.
Oncoimmunology|May 4, 2018
CD44v6 as innovative sarcoma target for CAR-redirected CIK cellsV Leuci, G M Casucci, G Grignani, et al.
Pageof 23

Showing results (161-170 of 230) with videos related to

Sort By:
Pageof 23
International Journal of Rheumatic Diseases|June 12, 2010
Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trialHsiao-Yi Lin, Tien-Tsai Cheng, Jyh-Horng Wang, et al.
Cardiovascular Therapeutics|September 3, 2011
Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugsHenry Krum, Gary Swergold, Arnold Gammaitoni, et al.
Current Medical Research and Opinion|June 29, 2012
Perioperative use of etoricoxib reduces pain and opioid side-effects after total abdominal hysterectomy: a double-blind, randomized, placebo-controlled phase III studyEugene R Viscusi, Tara L Frenkl, Craig T Hartrick, et al.
Breast Cancer Research and Treatment|December 15, 2010
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenibGiorgio Valabrega, Sonia Capellero, Giuliana Cavalloni, et al.
Human Gene Therapy|August 15, 2009
T cell receptor (TCR) gene transfer with lentiviral vectors allows efficient redirection of tumor specificity in naive and memory T cells without prior stimulation of endogenous TCRPaola Circosta, Luisa Granziero, Antonia Follenzi, et al.
Seizure|November 12, 2021
Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndromeJ Helen Cross, Bradley S Galer, Antonio Gil-Nagel, et al.
EJIFCC|October 23, 2023
Inter-laboratory method validation of CD34+ flow-cytometry assay: the experience of Turin Metropolitan Transplant CentreI F Ivana Ferrero, D R Deborah Rustichelli, S C Sara Castiglia, et al.
Journal of Biotechnology|September 22, 2011
Transient proteasome inhibition as a strategy to enhance lentiviral transduction of hematopoietic CD34(+) cells and T lymphocytes: implications for the use of low viral doses and large-size vectorsValeria Leuci, Giulia Mesiano, Loretta Gammaitoni, et al.
Frontiers in Oncology|February 23, 2023
Case report: Preclinical efficacy of NEDD8 and proteasome inhibitors in patient-derived models of signet ring high-grade mucinous colorectal cancer from a Lynch syndrome patientErica Torchiaro, Consalvo Petti, Sabrina Arena, et al.
Oncoimmunology|May 4, 2018
CD44v6 as innovative sarcoma target for CAR-redirected CIK cellsV Leuci, G M Casucci, G Grignani, et al.
Pageof 23